Risk of Cancer-related Death for Men with Biopsy Grade Group 1 Prostate Cancer and High-risk Features: A European Multi-institutional Study.

Autor:	Milonas D; Department of Urology, University Hospitals Leuven, Leuven, Belgium.; Department of Urology, Lithuanian University of Health Sciences, Kaunas, Lithuania., Giesen A; Department of Urology, University Hospitals Leuven, Leuven, Belgium.; Department of Development and Regeneration, KU Leuven, Leuven, Belgium., Muilwijk T; Department of Urology, University Hospitals Leuven, Leuven, Belgium., Soenens C; Department of Urology, University Hospitals Leuven, Leuven, Belgium., Devos G; Department of Urology, University Hospitals Leuven, Leuven, Belgium., Venclovas Z; Department of Urology, Lithuanian University of Health Sciences, Kaunas, Lithuania., Briganti A; Department of Urology, University Vita Salute, San Raffaele Hospital, Milan, Italy., Gontero P; Department of Urology, University of Turin, A.O.U. San Giovanni Battista-le Molinette, Turin, Italy., Karnes RJ; Department of Urology, Mayo Clinic, Rochester, MN, USA., Chlosta P; Department of Urology, Jagiellonian University Medical College, Krakow, Poland., Claessens F; Laboratory of Molecular Endocrinology, KU Leuven, Leuven, Belgium., De Meerleer G; Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium., Everaerts W; Department of Urology, University Hospitals Leuven, Leuven, Belgium.; Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium., Graefen M; Martini Klinik am UKE GmbH, Hamburg, Germany., Marchioro G; Department of Urology, University of Piemonte Orientale, Novara, Italy., Sanchez-Salas R; Department of Surgery, Division of Urology, McGill University, Montreal, Canada., Tombal B; Department of Urology, Cliniques Universitaires Saint Luc, Brussels, Belgium., Van Der Poel H; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Van Poppel H; Department of Urology, University Hospitals Leuven, Leuven, Belgium., Spahn M; Department of Urology, Lindenhofspital Bern, Bern, Switzerland., Joniau S; Department of Urology, University Hospitals Leuven, Leuven, Belgium.; Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Jazyk:	angličtina
Zdroj:	European urology open science [Eur Urol Open Sci] 2024 Jun 26; Vol. 66, pp. 33-37. Date of Electronic Publication: 2024 Jun 26 (Print Publication: 2024).
DOI:	10.1016/j.euros.2024.06.001
Abstrakt:	International Society of Urological Pathology grade group 1 (GG 1) prostate cancer (PCa) is generally considered insignificant, with recent suggestions that it should even be considered as "noncancerous". We evaluated outcomes for patients with GG 1 PCa on biopsy (bGG 1) and high-risk features (prostate-specific antigen [PSA] >20 ng/ml and/or cT3-4 stage) to challenge the hypothesis that every case of bGG 1 PCa has a benign disease course. We used the multi-institutional EMPaCT database, which includes data for 9508 patients with high-risk PCa undergoing surgery. We included patients with bGG 1 PCa ( n  = 848) in our analysis and divided them into three groups according to PSA >20 ng/ml, cT3-4 stage, or both. The estimated 10-yr cancer-specific survival (CSS) rate was 96% in the overall population, 88% in the group with both PSA >20 ng/ml and cT3-4 stage, 97% in the group with PSA >20 ng/ml alone, and 98% in the group with cT3-4 stage alone. Similar CSS outcomes were found in subgroups with GG 1 PCa on pathology ( n  = 502) and with GG 1 on biopsy diagnosed after 2005 ( n  = 253). Study limitations include the lack of magnetic resonance imaging (MRI) staging and MRI-targeted biopsies. In conclusion, patients with GG 1 and either PSA >20 ng/ml or cT3-4 stage have a low risk of dying from their cancer after surgery. However, patients with GG 1 PCa and both PSA >20 ng/ml and cT3-4 stage are at higher risk of cancer-specific mortality and active treatment should be discussed for this subgroup. Patient Summary: We assessed outcomes for patients diagnosed with low-grade prostate cancer on biopsy who also had one or two factors associated with high risk disease. Men with both of those risk factors had a higher risk of dying from their prostate cancer. Active treatment should be discussed for this subgroup of patients. (© 2024 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu